

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

2.16 2023

Chordia receives Development Milestone Payment of CTX-177 (ONO-7018), a MALT1 Inhibitor according to License Agreement with Ono Pharmaceutical

Kanagawa, Japan, February 16, 2023 – Chordia Therapeutics Inc. (“Chordia”), a biotech company engaged in the research and development of novel therapies for cancers, today announced that Chordia receives JPY2.5 billion from Ono Pharmaceutical Co., Ltd. (“ONO”), as one of the development milestones that is paid upon the achievement of the start of Phase 1 clinical trial under the license agreement for CTX-177 (ONO-7018), a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitor, concluded in December 2020 with ONO.

Under this agreement, Chordia has already received from ONO JPY0.8 billion of an upfront payment and receives JPY2.5 billion upon the achievement of this development milestone. In addition to these payments, Chordia will also receive from ONO up to JPY49.6 billion as milestones according to future development progress and sales. Chordia will also receive from ONO high-single digits to low double-digit tiered royalties based on global net sales of CTX-177 (ONO-7018).

Our CEO Hiroshi Miyake said, “We are pleased that the clinical development of CTX-177 (ONO-7018), a MALT1 inhibitor licensed to ONO, is progressing smoothly. We hope that the progress in clinical development activities by ONO will bring the new therapeutic drug for cancer patients as soon as possible.”

**About CTX-177 (ONO-7018)**

CTX-177 (ONO-7018) is a selective inhibitor against a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), which is known to be involved in an intracellular signaling pathway in lymphocytic blood cells. Activation of MALT1 is reported to play an important role in malignancies of lymphocytes. CTX-177 (ONO-7018) is expected to exert anti-tumor effect against these malignancies by inhibiting of MALT1 activity. CTX-177 (ONO-7018) is an investigational agent that has not been approved for any indication in any country. Safety and efficacy have not been established.

**About ONO Pharmaceutical Co., Ltd.**

Ono Pharmaceutical Co., Ltd., headquartered in Osaka, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. Ono focuses its research on the oncology, immunology, neurology and specialty research with high medical needs, as priority areas for discovery and

---

development of innovative medicines. For further information, please visit the company's website <https://www.ono-pharma.com/en>.

### **Important Notice**

In this press release, the definition of "press release" covers any oral presentation, question and answer session, and written and/or oral materials discussed or distributed by Chordia Therapeutics in connection with this press release. This press release (including the oral description and related questions and answers) is not intended to constitute, represent, or form part of any offer, invitation, or solicitation to purchase and/or acquire anything, including securities.

### **Disclaimer**

Any announcements by Chordia Therapeutics, including this press release, may contain information on products derived from pharmaceutical developments, but are intended to inform the latest information related to Chordia's business, and not intended as promotions, solicitations, advertisements, or to provide medical advice.

### **Forward-Looking Statements**

This press release and materials distributed in connection with this press release may contain forward-looking statements, information, beliefs, and opinions concerning our future operations, future positioning, and performance, including estimates, projections, goals, and plans. Forward-looking statements may include, but are not limited to, expressions such as "goals," "plans," "beliefs," "hopes," "continues," "expects," "intends," "assures," "will," "may," "should," "would," "could," "estimates," "projects," and/or other similar expressions, or the negative thereof. These forward-looking statements are based on assumptions concerning a number of important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements; highly influential factors that include economic conditions surrounding our global business, which include general economic conditions in Japan and the United States, competitive pressures and developments including changes in applicable laws and regulations, which include global healthcare reform, uncertainty as to our clinical success, and challenges inherent in new product development (which include regulatory decisions and their timing,) uncertainty as to the commercial success of new and existing products manufacturing difficulties, delays fluctuations in interest rates and exchange rates claims or concerns regarding the safety or efficacy of commercial products or product candidates the impact of a health crisis, such as the COVID-19 pandemic, on Chordia and its customers and suppliers (including foreign governments in countries in which the Company conducts business) or other aspects of its business. We undertake no obligation to update any forward-looking statements contained in this press release or any other forward-looking statements we may make, except as required by law or stock exchange rules. Past performance is not indicative of future operating results, and any of our operating results or statements in this press release are not estimates, forecasts, warranties, or projections of our future operating results.

## Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

info@chorditherapeutics.com



---

### **About Chordia Therapeutics**

Chordia was established in November 2017 at Shonan Health Innovation Park (“Shonan iPark”) in Fujisawa, Kanagawa Prefecture, as a biotech company engaged in the research and development of novel therapies for cancers, with the goal of researching and developing first-in-class anti-cancer drugs and creating innovative new drugs.

In addition to its leading program for CTX-712, Chordia is engaged in the research of several developments in our pipeline, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors.

Established: November 2017  
Address: 26-1, Muraoka-Higashi 2-chome, Fujisawa,  
Kanagawa 251-0012, Japan  
Representative: Hiroshi Miyake, Representative Director  
Website: <https://www.chorditherapeutics.com/en/>

For more information, contact, IR Team: [info@chorditherapeutics.com](mailto:info@chorditherapeutics.com)